2016
DOI: 10.1016/j.cden.2015.08.009
|View full text |Cite
|
Sign up to set email alerts
|

Chemical and Radiation-Associated Jaw Lesions

Abstract: Synopsis Osteonecrosis of the jaw, at one time considered to be infrequent has now become a major public health concern not only in the United States, but throughout the world. The wide-spread use of radiotherapy for head and neck cancer as well as bone antiresorptives and antiangiogenic agents have increased the incidence of osteonecrosis. While the exact pathophysiological process of osteonecrosis is yet to be clearly defined, there has been a much higher incidence of medication-related osteonecrosis of the … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
11
0
9

Year Published

2016
2016
2023
2023

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 28 publications
(20 citation statements)
references
References 44 publications
0
11
0
9
Order By: Relevance
“…Interestingly, bone loss in ameloblastoma associated with dysregulated RANK/RANKL/OPG interactions (de Matos et al , ) has led to the suggestion that antiresorptives such as denosumab may be effective in controlling the local aggressiveness of ameloblastoma (Jhamb and Kramer, ). Unfortunately, a major side effect of antiresorptives is osteonecrosis of the jaw (Akintoye and Hersh, ; Omolehinwa and Akintoye, ), so the potential clinical benefits must be balanced with their established side effects to justify their use in ameloblastoma therapy.…”
Section: Current Management Approaches In Ameloblastomamentioning
confidence: 99%
“…Interestingly, bone loss in ameloblastoma associated with dysregulated RANK/RANKL/OPG interactions (de Matos et al , ) has led to the suggestion that antiresorptives such as denosumab may be effective in controlling the local aggressiveness of ameloblastoma (Jhamb and Kramer, ). Unfortunately, a major side effect of antiresorptives is osteonecrosis of the jaw (Akintoye and Hersh, ; Omolehinwa and Akintoye, ), so the potential clinical benefits must be balanced with their established side effects to justify their use in ameloblastoma therapy.…”
Section: Current Management Approaches In Ameloblastomamentioning
confidence: 99%
“…Inside the oral cavity, any combination of dysgeusia, pain, paresthesia, exposed bone, gingival ulceration, poor dentition, fractured teeth, pathologic mandibular fracture, xerostomia, and orocutaneous fistula with associated discharge may be found. Palpation of soft and bony tissue may elicit pain (O'Dell and Sinha, ; Turner et al , ; Omolehinwa and Akintoye, ). Soft tissue woody fibrosis may be apparent, with severe cases experiencing a reduced range of motion at the temporomandibular joint or cervical spine.…”
Section: Osteoradionecrosis Of the Jaw (Orn)mentioning
confidence: 99%
“…(Lyons and Ghazali, ; Lyons et al , ) (Feldmeier, ; Rice et al , ). A concurrent cascade of cytokine release, particularly transforming growth factor beta (Fleckenstein et al , ), causes additional inflammation, tissue damage, and a decreased capacity for healing (Delanian and Lefaix, ; Omolehinwa and Akintoye, ). The use of tobacco products (Freiberger et al , ) or alcohol (Oh et al , ) also impedes healing.…”
Section: Osteoradionecrosis Of the Jaw (Orn)mentioning
confidence: 99%
“…Although most cases of ORN are related to high‐dose RT (5,000–7,000 cGy), ORN may also occur with lower radiation doses. Thus, it seems that dose alone is insufficient to predict absolute risk for ORN (Akintoye & Hersh, ; Danielsson et al, ; Omolehinwa & Akintoye, ; Reuther, Schuster, Mende, & Kübler, ).…”
Section: Introductionmentioning
confidence: 99%